These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17553209)

  • 21. Noninfective cutaneous granuloma with leuprorelin acetate--reality or myth.
    Dangle P; Palit V; Sundaram SK; Weston P
    Urology; 2007 Apr; 69(4):779.e5-6. PubMed ID: 17445679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case of foreign body granuloma induced by subcutaneous injection of leuprorelin acetate─clinical analysis for 335 cases in our hospital─.
    Kawai M; Ikoma N; Yamada A; Ota T; Manabe Y; Kato M; Mabuchi T; Ozawa A; Higure T; Terachi T
    Tokai J Exp Clin Med; 2014 Sep; 39(3):106-10. PubMed ID: 25248424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypersensitivity vasculitis associated with leuprolide (Lupron).
    Gnanaraj J; Saif MW
    Cutan Ocul Toxicol; 2010 Sep; 29(3):224-7. PubMed ID: 20470239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
    Shore ND; Sieber P; Schimke L; Perzin A; Olsen S
    Urol Nurs; 2013; 33(5):236-44, 248. PubMed ID: 24354113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
    Montgomery BS; Borwell JP; Higgins DM
    Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
    Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
    [No Abstract]   [Full Text] [Related]  

  • 29. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
    J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
    Doyle-Lindrud S
    Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 32. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 33. Pituitary Apoplexy After Initial Leuprolide Injection.
    Fabiano AJ; George S
    World Neurosurg; 2016 Nov; 95():616.e7-616.e9. PubMed ID: 27586180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic allergic dermatitis caused by the solvent of Eligard.
    Ruiz-Hornillos J; Henríquez-Santana A; Moreno-Fernández A; González IG; Sánchez SR
    Contact Dermatitis; 2009 Dec; 61(6):355-6. PubMed ID: 20059500
    [No Abstract]   [Full Text] [Related]  

  • 35. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation.
    Wong WW; Buskirk SJ; Schild SE; Prussak KA; Davis BJ
    J Urol; 2006 Nov; 176(5):2020-4. PubMed ID: 17070243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer.
    Sharifi R; Browneller R;
    J Urol; 2002 Sep; 168(3):1001-4. PubMed ID: 12187208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
    Stone NN; Stock RG; Unger P
    Mol Urol; 2000; 4(3):163-8;discussion 169-70. PubMed ID: 11062370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate.
    Watanabe T; Yamada N; Yoshida Y; Yamamoto O
    J Cutan Pathol; 2009 Dec; 36(12):1299-302. PubMed ID: 19469875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
    Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot].
    Jiménez Cruz JF; Vera Donoso CD; Iborra I; Solsona E; Forner E; Villavicencio H; Díaz C; González C; Rioja L; Pertusa C
    Actas Urol Esp; 1994 Feb; 18(2):90-3. PubMed ID: 7976707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.